Form 4: Zimmer Biomet Director Maria Teresa Hilado Reports Acquisition of Phantom Stock Units

Director Maria Teresa Hilado reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. under the deferred compensation plan.

Summary

• Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 on April 02, 2025.
• The report details the acquisition of 244.423 phantom stock units on March 31, 2025, at a price of $112.51 per unit.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The units will be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
• Hilado directly owns 9,302.622 shares of common stock, which includes 19.144 phantom stock units accrued on January 31, 2025, under the dividend reinvestment provision of the deferred compensation plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding director compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan encourages directors to remain invested in the company's success.

Future Outlook

The phantom stock units will be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Industry Context

This filing is a routine disclosure related to director compensation and is common in publicly traded companies. It reflects standard practices for aligning director incentives with shareholder value.

Comparison to Industry Standards

• Deferred compensation plans for non-employee directors are a common practice among publicly traded companies, including Zimmer Biomet's competitors such as Stryker Corporation and Johnson & Johnson.
• These plans typically involve granting phantom stock units or restricted stock units that vest over time and are settled in cash or stock upon the director's departure from the board.
• The specific terms of these plans, such as the vesting schedule and settlement method, can vary depending on the company's compensation philosophy and governance practices.

Stakeholder Impact

• Shareholders may view the director's participation in the deferred compensation plan as a positive sign, aligning their interests with the company's long-term success.

Key Dates

Keywords

Zimmer Biomet, Director, Maria Teresa Hilado, Phantom Stock Units, Deferred Compensation Plan, Form 4, Beneficial Ownership, ZBH